

Enhancing Quality through Innovation

Presentation to the National Cancer Advisory Board

**on behalf of
The American Society of Clinical Oncology**

Supplemental Slides

September 15, 2009



Cooperative Group Poll

- **Methodology:**

- Internet based poll, used SurveyMonkey.com to collect answers.
- Poll was open from August 19 until September 3rd
- Provided each Cooperative Group a unique link to send to their members. EORTC did not participate.
- ASCO was not given access to membership lists and relied on the cooperative group chairs (and administrators) to send the poll out. SWOG requested that ASCO use its list to send the survey out.
- Number of recipients unknown, but used NCI's number of ~1800 sites that enrolled a trial participant in 2008 as a baseline.
- Sites belonging to multiple Cooperative Groups may have received multiple links to the poll, but were asked to complete only one poll per site.
- Multiple responses from the same site were identified, contacted and corrected (if needed) to ensure no overlap in responses.
- 566 started the poll. 478 complete responses were received.

- **Limitations of poll:**

- Unclear if 478 responses are representative of all Cooperative Group sites



Institution Response Rate

Academic Medical Center

186

Hospital, Non-Academic

130

Private Practice


75

Other

25

No Response

64



Respondents that classified themselves as "other" include:
Government Institutions (VA, NIH)
Academic Affiliates
CCOPs
HMOs
Hospital-owned practices®

Total number of responses: 478



Preference for Cooperative Group Trials

- Unsolicited comments from respondents:
 - *“Focus is to open and accrue to NCI sponsored trials”*
 - *“No change in current policy: Open [industry trials] if not competing with NCI trials”*
 - *“Our focus is on Cooperative Group Trials”*
 - *“Consider only trials that ask a valid scientific question rather than pre-marketing studies”*
 - *“Cooperative group trials are the first priority”*

Other Reasons for Limiting Cooperative Group Participation

- Unsolicited comments from respondents:
 - *“Investigator initiated trials are more important for the NCI designation”*
 - *“No pressure on Leadership of Cancer Center from the NCI to support Cooperative Group Trials (versus the extreme pressure felt by the Leadership of our Cancer Center to enhance ‘Investigator-Initiated Studies’”*
 - *“We could have staff if we had funding”*
 - *“Too much work to open trials for rare conditions that won't accrue”*